BNET Industries
Vanda Pharmaceuticals Inc. (VNDA) is in the Pharma Industry
- Profit
- Dec 31 2007
- ($74.0M)
- Market Cap
- Dec 02 2008
- $15.4M
Latest News and Analysis
Vanda Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Operator instructions Your first question comes from the line of Corey Davis from Natexis. Please proceed. Corey Davis – Natexis Thanks very much. I guess in the meaning that you have when you have it with the FDA, what’s ambiguous about the letter that could...
Vanda Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
Question-and-Answer Session Operator Operator instructions Your first question will come from the line of Corey Davis representing Natixis. Please Proceed. Corey Davis – Natixis Bleichroeder Thanks very much. A Geodon ZODIAC study is now out and been presented a couple times and Pfizer has done very...
Vanda Pharmaceuticals Q4 2007 Earnings Call Transcript
Question-and-Answer SessionOperator Thank you. Operator Instructions Your first question comes from the line of Adam Greene with JP Morgan. Please proceed. Adam Greene-J P Morgan Thanks, good morning, happy Valentines Day everyone. Two questions, one I was wondering if you have any thoughts following the...
Additional Resources
FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
ROCKVILLE, Md., Nov. 20 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, reported today that the FDA has accepted Vanda's resubmission of the iloperidone New Drug Application NDA. Vanda's resubmission was...
Addiction Therapeutics Reviewed by NeuroInvestment
NI Research today announced the release of theNovember issue of NeuroInvestment, featuring a review of pharmacologictherapeutics for addiction. The interface of the biological andsociocultural factors involved in substance abuse is reviewed foraddictions to alcohol, opioids, stimulants methamphetamines and cocaine,and nicotine. Programs under development by over 25 companies are included in...
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2008. Vanda reported research and development...
Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
ROCKVILLE, Md., Sept. 25 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, announced today that the Board of Directors of Vanda Pharmaceuticals Inc. (the "Company") declared a dividend distribution of one Preferred Share...
Vanda Pharmaceuticals Provides Update on Iloperidone
ROCKVILLE, Md., Sept. 11 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, reported today that it met with the FDA on September 10, 2008 and discuss the iloperidone non-approvable action letter that the...
The Daily Record News Briefs: August 6, 2008
Bank's money orders 'missing' BCSB Bancorp Inc., the holding company for Baltimore County Savings Bank FSB, issued a "special alert" that money orders bearing the bank's name and serial numbers 01000101 through 01000599 "are missing, lost or stolen," and said it has notified the Federal Deposit Insurance...
Sucampo Pharmaceuticals Appoints Jan Smilek Acting Chief Financial Officer
Company Names Chief Accounting Officer to Lead Finance Team BETHESDA, Md. -- Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) announced the appointment of the company's Chief Accounting Officer, Jan Smilek, to the position of Acting Chief Financial Officer, effective immediately. Smilek replaces former Chief Financial Officer Mariam E. Morris, who...
FDA Issues Not Approvable Letter for Iloperidone to Vanda Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) has received a not approvable letter for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia, from the U.S. Food and Drug Administration FDA. Vanda, the sub-licensee for iloperidone, is responsible for the...
BellwetherReport.com Analyst Report on VNDA, SOHU, RYAAY and XOHO
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...
Neuro Sector Reviewed by NeuroInvestment
NeuroInvestment today announced the release ofits July/August issue, which overviews the CNS sector at midyear, andpreviews the second half of 2008. The major news at midyear was theAlzheimer's data which came from high-profile programs at Elan/Wyeth and atMyriad Genetics. The issue takes a hard look at those results, and notesthe...
BellwetherReport.com Analyst Report on URRE, GOOG, HCBK and VNDA
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...
Rockville-based Vanda, LabCorp form alliance
Vanda Pharmaceuticals Inc., of Rockville, a biopharmaceutical company that is developing drugs to treat disorders of the central nervous system, and Laboratory Corporation of America Holdings, of Burlington, N.C., one of the world's largest providers of laboratory testing services, announced an alliance to develop and commercialize a series of diagnostic...
LabCorp® and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
BURLINGTON, N.C. & ROCKVILLE, Md. -- Laboratory Corporation of America[R] Holdings (LabCorp[R]) (NYSE:LH), one of the world's leading clinical trials and genetic testing laboratories, and Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced...
Wall Street News Alert Issues Special Alert on OCOL! May 6, 2008
Wall Street News Alert's "stocks to watch" thismorning are: Oncolin Therapeutics (OTCBB: OCOL), Vanda Pharmaceuticals Inc.(NASDAQ: VNDA), Millennium Pharmaceuticals, Inc. (NASDAQ: MLNM), GileadSciences, Inc. (NASDAQ: GILD). There is more important news coming from Oncolin Therapeutics (OTCBB: OCOL), and the company should have investors monitoring the stock thismorning. Yesterday after the...
New Analyst Reports for ALBERTA OILSANDS INC, RUBICON MINERALS CORPORATION, ZOLTEK COMPANIES INC, and VANDA PHARMACEUTICALS INC
MaybachFinancial.com is one of the fastest growingindependent and unbiased research firms in the world. Through our numerouspartnerships with many of the top investment minds in the world, we provideresearch on companies making a move in the markets. Investors seekinggenuine analyst opinions on their investments for ALBERTA OILSANDS INC(TSX-V: AOS), RUBICON...
Md.-based Vanda Pharmaceuticals Inc. announces first-quarter net
Vanda Pharmaceuticals Inc., of Rockville, which develops drugs to treat disorders of the central nervous system, reported a first- quarter net loss of $19.2 million, or 72 cents per diluted share, on zero revenue, compared to a net loss of $15.4 million, or 61 cents per diluted share, on zero...
Titan Pharmaceuticals Announces Fourth Quarter and Year-End 2007 Financial Results
Significant Clinical Development Milestones Expected in 2008; Conference Call Today at 10:30 A.M. EDT SOUTH SAN FRANCISCO, Calif. -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today reported financial results for the fourth quarter and full year ended December 31, 2007. "Throughout 2007, we made significant progress in each...
- Next »
- page 1 of 1
- « Previous
Sort byClose
- Incorporated: 2002
- CEO: Dr. Mihael H. Polymeropoulos M.D.
- Employees: 44
Vanda Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing clinical-stage drug candidates, with exclusive worldwide commercial rights to three product candidates in clinical development for various central nervous system disorders. Its lead product candidate, iloperidone, is a compound for schizophrenia and bipolar disorder treatment. Meanwhile, its second product candidate, VEC-162, is a compound for sleep and mood disorders treatment. Additionally, Co.'s third product candidate, VSF-173, is a compound for excessive sleepiness treatment and is ready for a phase II trial.
Key Competitors
Industry Transcripts by Seeking Alpha
-
Indevus Pharmaceuticals, Inc. F4Q08 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 25, 2008about IDEV
-
Noven Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about NOVN
-
XenoPort, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about XNPT
-
Repligen Corporation F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 24, 2008about RGEN
-
Omrix Biopharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about OMRI
Vanda Pharmaceuticals Inc. Company Info
Board of Directors
Dr. Argeris N. Karabelas Ph.D.
Chairman
Dr. Mihael H. Polymeropoulos M.D.
Mr. Richard W. Dugan
Dr. Brian K. Halak Ph.D.
Mr. H. Thomas Watkins
Mr. David Ramsay
Mr. Howard H. Pien
Contact Information
9605 Medical Center Drive
Suite 300
Rockville, MD
240 599-4500
